Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
GLP-1 medications are considered long-term, chronic-disease therapies for both diabetes and obesity
Quality assurance measures for GLP-3 RT include: Third-party HPLC verification of peptide purity for every production batch Mass spectrometry (MS) analysis to confirm molecular identity and integrity Certificate of Analysis (CoA) provided with each order for full research traceability Lyophilization and controlled packaging to preserve peptide stability during transit Batch-specific lot numbering for quality tracking and documentation These standards reflect Novaglo Researchs commitment to supplying research-grade compounds that meet the documentation and reproducibility requirements expected in professional laboratory settings
Weight loss medications, including compounded Semaglutide, compounded Tirzepatide, Phentermine, Phentermine +Topiramate, and Metformin, are prescribed to support lifestyle changes like diet and exercise when specific criteria are met
2025, Kellner, D
